Tagged with Oncology

Singapore Vishal Doshi, founder and CEO of AUM Biosciences, shares his motivation behind establishing the company and his mission to build an ecosystem within AUM for a decentralized biotech innovation model; their focus on oncology and specifically small molecule cancer therapies; and the critical importance of the China market within their…

China Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the individual patient’s tumor microenvironment; their strategy to differentiate their approaches to in-licensing as well as combination plays within the area…

Switzerland With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard of countering a disease which the World Health Organization (WHO) predicts will reach an incidence rate of 22 million new…

Oncology Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that it believes would drastically improve cancer mortality rates and quality of life for oncology patients.   Recent statistics show that…

Taiwan James Chiu, GM of Fresenius Kabi Taiwan, discusses the affiliate’s portfolio offering of parenteral and enteral nutrition in Taiwan as well as its move towards biosimilars. In addition, Chiu highlights the importance of the Taiwanese affiliate to the Asia Pacific region, product developments locally, and partnerships with domestic players.  …

Sweden Ascelia Pharma is a Swedish oncology start-up based in Malmö. CEO Magnus Corfitzen talks about the opportunities they have found in the orphan oncology drug market, the promising phase III study for their lead asset, Mangoral, and his journey navigating the Swedish life science industry.   With Mangoral, we are…

China The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial efficacy evaluation.   19 of 24 patients with relapsed and refractory multiple myeloma showed complete response Zonghai Li, CARSgen Therapeutics…

China Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which is Old Norse for ‘to cure, to heal’. He also outlines Laekna’s focus on disease biology, specifically the areas of…

Thailand Dr Ekaphop Sirachainan, president of the Thai Society of Clinical Oncology, explains the need to increase patient access to oncology treatment in Thailand, and the crucial need for collaboration with the public sector in terms of prevention and to spread information to all healthcare professionals. Sirachainan also underlines the importance…

China Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed PD-1 cancer drug (toripalimab) in China, their commercialization and pricing strategies and the exciting new products and milestones that we…

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

China Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019.   I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to…